Cure My Disease

Don't miss your cure!

 Log in / Sign up

Common antibiotic may shield Kids' hearts from kawasaki disease damage

NCT ID NCT01917721

Disease control Sponsor: Hawaii Pacific Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the antibiotic doxycycline can prevent or slow the enlargement of heart arteries in children with Kawasaki disease. About 26 children with already enlarged coronary arteries will receive doxycycline for three weeks. The goal is to see if the drug blocks a harmful substance linked to artery damage and reduces the risk of serious heart problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

26 people

The number who actually took part.

Started

Oct 2013

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

1 month to 21 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Treatment arm: Patients aged 1 month to 21 years with confirmed KD will be included in the study if they meet the following criteria: 1. Patients with dilation of the right or left anterior descending coronary artery beyond a z-score of +2.5 during the acute febrile phase of KD. 2. Patients with aneurysms of the right or left main coronary arteries during the acute febrile phase of KD. 3. Patients with refractory KD after initial treatment with IVIG and dilated coronary arteries on an echocardiogram during the first month of KD. Comparison arm: Patients aged 1 month to 18 years with confirmed KD, who do not meet inclusion criteria to be included in the treatment group. 1.Patients with right or left anterior descending coronary artery measurements below a z-score of +2.5 during the acute febrile phase of KD. Exclusion Criteria: The following patients will be excluded from this study: 1. Patients with clinically incomplete KD. 2. Patients whose parents refuse to administer doxycycline. 3. Patients with acute renal failure. 4. Patients with chronic liver and kidney disease.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary aneurysm are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary aneurysm Kawasaki disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary aneurysm Kawasaki disease

Contacts and locations

Locations

  • Kapiolani Medical Center for Women and Children

    Honolulu, Hawaii, 96826, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.